Breast cancer is the second-leading cause of cancer death among women in the United States. Although medicines such as Herceptin® have changed the course of HER2-positive breast cancer, it remains an aggressive form of the disease, and new medicines are needed for women with advanced disease.
The Memorial Healthcare System is participating in the CLEOPATRA study, a Phase III global clinical research study, to determine if the investigational medicine, pertuzumab — when given with a commonly used targeted cancer treatment, Herceptin, and chemotherapy — is safe and effective, compared to an inactive placebo, Herceptin, and chemotherapy.
To be eligible for the CLEOPATRA study, participants must be at least 18 years old, have HER2-positive metastatic breast cancer, and cannot have received treatment after the cancer has spread to other parts of the body. The Memorial Healthcare System is one of 80 institutions across the country seeking study participants.
“Research into new treatments is vital to continue the progress being made against this deadly disease,” said Dr. Alejandra Perez, Director of Breast Cancer for the Memorial Healthcare System. “The CLEOPATRA study will tell us more about pertuzumab’s potential role in treating women in the future with HER2-positive metastatic breast cancer.”
To determine if you may be eligible to participate in the CLEOPATRA study, please visit www.HER2study.com or call 1-888-662-6728.